内克塔治疗(NKTR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NKTR 内克塔治疗

已收盘 05-07 16:00:00 EDT

83.37

-1.72

-2.02%

盘后82.75

-0.62-0.74%

19:55 EDT

最高85.82	最低81.82	成交量76.46万
今开85.00	昨收85.09	日振幅4.70%
总市值28.13亿	流通市值24.61亿	总股本3,374万
成交额6,364万	换手率2.59%	流通股本2,951万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NKTR","market":"US","secType":"STK","nameCN":"内克塔治疗","latestPrice":83.37,"timestamp":1778184000000,"preClose":85.09,"halted":0,"volume":764556,"hourTrading":{"tag":"盘后","latestPrice":82.75,"preClose":83.37,"latestTime":"19:55 EDT","volume":4318,"amount":359426.6761,"timestamp":1778198102714,"change":-0.62,"changeRate":-0.007437,"amplitude":0.014993},"delay":0,"changeRate":-0.02021389117405099,"floatShares":29514600,"shares":33742100,"eps":-9.73,"marketStatus":"已收盘","change":-1.72,"latestTime":"05-07 16:00:00 EDT","open":85,"high":85.82,"low":81.82,"amount":63641603.21219999,"amplitude":0.047009,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-9.73,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1778227200000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":85.09,"preHourTrading":{"tag":"盘前","latestPrice":85.5,"preClose":85.09,"latestTime":"09:25 EDT","volume":18698,"amount":1591254.2111799999,"timestamp":1778160336246,"change":0.41,"changeRate":0.004818,"amplitude":0.010577},"postHourTrading":{"tag":"盘后","latestPrice":82.75,"preClose":83.37,"latestTime":"19:55 EDT","volume":4318,"amount":359426.6761,"timestamp":1778198102714,"change":-0.62,"changeRate":-0.007437,"amplitude":0.014993},"volumeRatio":1.134639,"impliedVol":0.6375,"impliedVolPercentile":0.088},"requestUrl":"/m/hq/s/NKTR","defaultTab":"news","newsList":[{"id":"1193135314","title":"财报前瞻｜内克塔治疗本季度营收预计同比-30.74%，看多观点占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1193135314","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193135314?lang=zh_cn&edition=full","pubTime":"2026-05-01 00:39","pubTimestamp":1777567157,"startTime":"0","endTime":"0","summary":"内克塔治疗将于2026年05月07日（盘后）发布财报，市场关注营收回落与临床推进下的费用与亏损趋势。当前一致预期显示，本季度内克塔治疗营收预计为1,063.62万美元，同比-30.74%；每股收益预计为-1.60，同比+35.29%；息税前利润预计为-3,956.11万美元，同比-32.68%；未检索到本季度毛利率和净利润的明确预测，相关指标暂不展示。市场预计本季度营收为1,063.62万美元，同比-30.74%，主要受非现金版税摊销节奏影响，收入基数环比上季明显下行。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜内克塔治疗本季度营收预计同比-30.74%，看多观点占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132475222","title":"内克塔治疗计划将净收益用于研发、临床开发及一般公司用途","url":"https://stock-news.laohu8.com/highlight/detail?id=1132475222","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132475222?lang=zh_cn&edition=full","pubTime":"2026-04-21 04:03","pubTimestamp":1776715391,"startTime":"0","endTime":"0","summary":"生物技术公司内克塔治疗（Nektar Therapeutics）宣布，其获得的净收益将主要投入研发活动、临床项目推进以及满足一般企业运营需求。此举旨在加速公司管线药物的开发进程，并为日常运营提供资金支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628724318","title":"美股异动 | 斑秃治疗药物试验取得预期结果 内克塔治疗(NKTR.US)暴涨超24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628724318","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628724318?lang=zh_cn&edition=full","pubTime":"2026-04-20 23:01","pubTimestamp":1776697275,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周一，内克塔治疗早盘暴涨超24%，年内累涨150%。在发布斑秃研究延长期治疗结果后，Oppenheimer公司重申了对内克塔治疗股票的“跑赢大盘”评级和140.00美元的目标价，认为24g/kg剂量组在第52周的综合SALT≤20应答率约为28%，符合其最佳预期范围。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132398328","title":"内克塔治疗股价盘前飙升17.8% 斑秃疗法扩展研究展现潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1132398328","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132398328?lang=zh_cn&edition=full","pubTime":"2026-04-20 20:30","pubTimestamp":1776688214,"startTime":"0","endTime":"0","summary":"内克塔治疗公司股价在盘前交易中大幅上涨17.8%，此前其针对斑秃的治疗方案在扩展研究中显示出积极前景。这项延续性研究结果增强了投资者对该疗法商业化潜力的信心，推动公司市值显著提升。\n临床数据显示，该疗法在长期用药情况下仍能维持疗效，为受斑秃困扰的患者提供了新的治疗希望。市场观察人士指出，这一突破性进展可能重塑自身免疫性疾病治疗领域的竞争格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144614206","title":"内克塔治疗：94%患者完成治疗延长期 实现临床显著毛发增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1144614206","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144614206?lang=zh_cn&edition=full","pubTime":"2026-04-20 19:34","pubTimestamp":1776684867,"startTime":"0","endTime":"0","summary":"生物技术公司内克塔治疗公布的最新临床数据显示，在接受治疗延长期方案的患者群体中，高达94%的参与者顺利完成全程治疗，并展现出具有临床意义的毛发增长效果。这一突破性进展为脱发治疗领域注入了新的希望。\n研究结果表明，绝大多数患者在延长治疗周期后不仅保持了治疗依从性，更在毛发再生指标上获得实质性改善。该数据进一步验证了治疗方案在长期应用中的有效性与安全性，为后续商业化推广提供了有力支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154617428","title":"Rezolve-AA研究16周双盲延长期52周顶线结果：Rezpegaldesleukin在重度至极重度斑秃患者中展现疗效持续深化","url":"https://stock-news.laohu8.com/highlight/detail?id=1154617428","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154617428?lang=zh_cn&edition=full","pubTime":"2026-04-20 19:32","pubTimestamp":1776684765,"startTime":"0","endTime":"0","summary":"Rezolve-AA临床研究最新公布的52周顶线数据显示，在完成16周双盲治疗延长期后，Rezpegaldesleukin对重度至极重度斑秃患者展现出持续深化的治疗效果。这项关键性延伸研究进一步验证了该疗法在长期用药过程中的应答强化趋势，为斑秃治疗领域提供了新的临床证据。\n斑秃作为一种自身免疫性疾病，其重度患者群体长期面临治疗选择有限的困境。此次公布的延长期结果不仅证实了治疗效果的持续性，更显示出随着用药时间的延长，患者临床应答程度呈现逐步加深的积极态势。该发现对推进斑秃治疗方案的优化具有重要意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109702235","title":"内克塔治疗将于2026年4月20日召开电话会议 讨论Rezpegaldesleukin治疗斑秃的Rezolve-AA二期B研究16周延长期52周顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1109702235","media":"美股速递","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109702235?lang=zh_cn&edition=full","pubTime":"2026-04-20 00:01","pubTimestamp":1776614476,"startTime":"0","endTime":"0","summary":"内克塔治疗宣布，公司计划于2026年4月20日举行一场电话会议，重点讨论其药物Rezpegaldesleukin用于治疗斑秃的Rezolve-AA二期B期临床研究的最新数据。\n此次会议将深入解读该研究16周延长治疗期结束后获得的52周顶线结果。这些关键数据将有助于评估该疗法在斑秃患者中的长期疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107219160","title":"财报前瞻 ｜内克塔治疗本季度营收预计同比为-0.65，看多观点占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1107219160","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107219160?lang=zh_cn&edition=full","pubTime":"2026-03-05 10:46","pubTimestamp":1772678772,"startTime":"0","endTime":"0","summary":"内克塔治疗将在2026年03月12日发布最新季度财报，市场关注收入结构与管线节点对盈利和估值路径的影响。市场一致预期显示，本季度内克塔治疗营收预计为1,040.36万美元，同比为-0.65；调整后每股收益预计为-2.47美元，同比为0.02；息税前利润预计为-4,023.69万美元，同比为-0.26；目前未检索到本季度的毛利率与净利率预测，相关指标暂不展示。公司上季度财报未披露对本季度收入的明确指引。财务层面，净利润环比为0.15，体现费用端的阶段性收敛。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻 ｜内克塔治疗本季度营收预计同比为-0.65，看多观点占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129516592","title":"内克塔治疗宣布与加州大学旧金山分校及Stephen Hauser博士就TNFR2抗体NKTR-0165在多发性硬化症领域展开研究合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1129516592","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129516592?lang=zh_cn&edition=full","pubTime":"2026-02-17 20:03","pubTimestamp":1771329786,"startTime":"0","endTime":"0","summary":"内克塔治疗（Nektar Therapeutics）宣布，将与加州大学旧金山分校（UCSF）及著名神经学专家Stephen Hauser博士建立研究合作关系，共同推进其肿瘤坏死因子受体2（TNFR2）抗体药物NKTR-0165在多发性硬化症领域的研发工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611767849","title":"内克塔治疗盘中异动 早盘股价大跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2611767849","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611767849?lang=zh_cn&edition=full","pubTime":"2026-02-12 22:31","pubTimestamp":1770906694,"startTime":"0","endTime":"0","summary":"北京时间2026年02月12日22时31分，内克塔治疗股票出现异动，股价急速跳水5.00%。截至发稿，该股报63.03美元/股，成交量94.1498万股，换手率4.63%，振幅2.09%。机构评级方面，在所有8家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。内克塔治疗股票所在的生物技术行业中，整体涨幅为0.14%。内克塔治疗公司简介：Nektar Therapeutics 是一家临床阶段，以研究为基础的药物发现生物制药公司，专注于发现和开发免疫治疗领域的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212223134a49ce7cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212223134a49ce7cd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194137925","title":"内克塔治疗将于2026年2月10日召开电话会议 讨论Rezpegaldesleukin治疗特应性皮炎IIb期REZOLVE-AD研究36周维持期顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1194137925","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194137925?lang=zh_cn&edition=full","pubTime":"2026-02-10 05:16","pubTimestamp":1770671773,"startTime":"0","endTime":"0","summary":"内克塔治疗宣布，公司计划于2026年2月10日举行电话会议，专门讨论其候选药物Rezpegaldesleukin在特应性皮炎领域IIb期REZOLVE-AD研究中，36周维持治疗阶段的顶线结果。此次会议将聚焦于这一关键临床试验的重要数据披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603363905","title":"内克塔治疗盘中异动 急速下挫5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603363905","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603363905?lang=zh_cn&edition=full","pubTime":"2026-01-13 23:13","pubTimestamp":1768317226,"startTime":"0","endTime":"0","summary":"北京时间2026年01月13日23时13分，内克塔治疗股票出现异动，股价大幅下跌5.00%。截至发稿，该股报36.83美元/股，成交量16.183万股，换手率0.80%，振幅5.08%。机构评级方面，在所有9家参与评级的机构中，89%的券商给予买入建议，11%的券商给予持有建议，无券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体跌幅为0.42%。内克塔治疗公司简介：Nektar Therapeutics 是一家临床阶段，以研究为基础的药物发现生物制药公司，专注于发现和开发免疫治疗领域的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011323134697a1a918&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011323134697a1a918&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602349969","title":"内克塔治疗盘中异动 临近收盘急速下跌5.19%报41.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602349969","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602349969?lang=zh_cn&edition=full","pubTime":"2026-01-09 04:37","pubTimestamp":1767904648,"startTime":"0","endTime":"0","summary":"北京时间2026年01月09日04时37分，内克塔治疗股票出现异动，股价大幅下跌5.19%。截至发稿，该股报41.25美元/股，成交量37.2958万股，换手率1.83%，振幅5.61%。机构评级方面，在所有9家参与评级的机构中，89%的券商给予买入建议，11%的券商给予持有建议，无券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体跌幅为1.90%。内克塔治疗公司简介：Nektar Therapeutics 是一家临床阶段，以研究为基础的药物发现生物制药公司，专注于发现和开发免疫治疗领域的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109043728a4ad3e5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109043728a4ad3e5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595117357","title":"内克塔治疗盘中异动 大幅下跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595117357","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595117357?lang=zh_cn&edition=full","pubTime":"2025-12-30 03:46","pubTimestamp":1767037570,"startTime":"0","endTime":"0","summary":"北京时间2025年12月30日03时46分，内克塔治疗股票出现异动，股价急速下挫5.03%。截至发稿，该股报42.25美元/股，成交量46.1589万股，换手率2.27%，振幅4.65%。机构评级方面，在所有9家参与评级的机构中，89%的券商给予买入建议，11%的券商给予持有建议，无券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体跌幅为0.64%。内克塔治疗公司简介：Nektar Therapeutics 是一家临床阶段，以研究为基础的药物发现生物制药公司，专注于发现和开发免疫治疗领域的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230034610a48722ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230034610a48722ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111891041","title":"Nektar Therapeutics股价在盘前交易中下跌2.4%，因其自身免疫疾病药物未能达到中期研究的主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=1111891041","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111891041?lang=zh_cn&edition=full","pubTime":"2025-12-16 21:45","pubTimestamp":1765892748,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics股价在盘前交易中下跌2.4%，因其自身免疫疾病药物未能达到中期研究的主要目标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180977691","title":"内克塔治疗 - Rezolve-Aa二期B研究结果支持进入斑秃的三期开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1180977691","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180977691?lang=zh_cn&edition=full","pubTime":"2025-12-16 21:16","pubTimestamp":1765890968,"startTime":"0","endTime":"0","summary":"内克塔治疗 - Rezolve-Aa二期B研究结果支持进入斑秃的三期开发","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190845593","title":"内克塔治疗 - Rezpegaldesleukin治疗组均满足统计显著性标准，排除违规情况","url":"https://stock-news.laohu8.com/highlight/detail?id=1190845593","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190845593?lang=zh_cn&edition=full","pubTime":"2025-12-16 21:07","pubTimestamp":1765890469,"startTime":"0","endTime":"0","summary":"内克塔治疗 - Rezpegaldesleukin治疗组均满足统计显著性标准，排除违规情况","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101661185","title":"内克塔治疗 - Rezolve-Aa II期B研究达成目标产品特征，盐分评分降低28.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1101661185","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101661185?lang=zh_cn&edition=full","pubTime":"2025-12-16 21:07","pubTimestamp":1765890441,"startTime":"0","endTime":"0","summary":"内克塔治疗 - Rezolve-Aa II期B研究达成了目标产品特征，盐分评分降低了28.2%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125532009","title":"Nektar将在2025年12月16日召开电话会议，讨论其Rezolve-Aa II期研究中Rezpegaldesleukin在脱发症中的36周诱导治疗期的初步结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1125532009","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125532009?lang=zh_cn&edition=full","pubTime":"2025-12-16 07:00","pubTimestamp":1765839610,"startTime":"0","endTime":"0","summary":"Nektar将在2025年12月16日召开电话会议，讨论其Rezolve-Aa II期研究中Rezpegaldesleukin在脱发症中的36周诱导治疗期的初步结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173506245","title":"Nektar Therapeutics第三季度每股收益为-1.87美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1173506245","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173506245?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:04","pubTimestamp":1763571844,"startTime":"0","endTime":"0","summary":"11月6日 - 内克塔治疗第三季度的运营收入为-316,720,000美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nektar.com","stockEarnings":[{"period":"1week","weight":0.0227},{"period":"1month","weight":0.1388},{"period":"3month","weight":1.4228},{"period":"6month","weight":0.5203},{"period":"1year","weight":7.8359},{"period":"ytd","weight":1.0125}],"compareEarnings":[{"period":"1week","weight":0.0313},{"period":"1month","weight":0.1137},{"period":"3month","weight":0.083},{"period":"6month","weight":0.0937},{"period":"1year","weight":0.3132},{"period":"ytd","weight":0.0761}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Nektar Therapeutics于1990年在加州成立，并于1998年重新在特拉华州注册。该公司是一家临床阶段、研究型药物发现生物制药公司，专注于发现和开发免疫治疗领域的创新药物。在这个不断增长的领域内，该公司致力于创造新的免疫调节剂，选择性地诱导、放大、减弱或阻止免疫反应，以达到预期的治疗效果。","yearOnYearQuotes":[{"month":1,"riseRate":0.53125,"avgChangeRate":0.03787},{"month":2,"riseRate":0.53125,"avgChangeRate":0.029488},{"month":3,"riseRate":0.40625,"avgChangeRate":-0.000642},{"month":4,"riseRate":0.46875,"avgChangeRate":0.016904},{"month":5,"riseRate":0.375,"avgChangeRate":0.003028},{"month":6,"riseRate":0.40625,"avgChangeRate":0.024924},{"month":7,"riseRate":0.4375,"avgChangeRate":-0.019557},{"month":8,"riseRate":0.46875,"avgChangeRate":0.044887},{"month":9,"riseRate":0.5,"avgChangeRate":0.042479},{"month":10,"riseRate":0.375,"avgChangeRate":-0.023288},{"month":11,"riseRate":0.6875,"avgChangeRate":0.087128},{"month":12,"riseRate":0.59375,"avgChangeRate":0.015542}],"exchange":"NASDAQ","name":"内克塔治疗","nameEN":"Nektar Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"内克塔治疗(NKTR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供内克塔治疗(NKTR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"内克塔治疗,NKTR,内克塔治疗股票,内克塔治疗股票老虎,内克塔治疗股票老虎国际,内克塔治疗行情,内克塔治疗股票行情,内克塔治疗股价,内克塔治疗股市,内克塔治疗股票价格,内克塔治疗股票交易,内克塔治疗股票购买,内克塔治疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"内克塔治疗(NKTR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供内克塔治疗(NKTR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}